NCT01319903View on ClinicalTrials.gov

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Drug Safety
Interventions
BIOLOGICAL

CaCP29, a humanized monoclonal antibody

CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males

Trial Locations (1)

41460

FOCUS Clinical Drug Development GmbH, Neuss

Sponsors

Lead Sponsor

InflaRx GmbH
All Listed Sponsors
lead

InflaRx GmbH

INDUSTRY

NCT01319903 - Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 | Biotech Hunter | Biotech Hunter